The Catalan multinational is focusing its future plans on the development of new injectable medical devices within its mesohyal™ and mesofiller® lines.
The pharmaceutical firm exports over 80% of its production, and it is consolidating its position as a benchmark not only in mature markets like Europe but also in other international markets such as China and the Middle East.

mesoestetic Pharma Group has just presented the results of its economic balance sheet for 2017, showing a turnover growth of 17%. The firm's success in 2017 is the result of the quality and reputation of its laboratory treatments and a healthy sector, as well as its investments in pioneering projects and the development of products and equipment of reference among physicians and aesthetics professionals.

In the words of its founder and CEO, Joan Carles Font, “2017 was a very positive year for mesoestetic Pharma Group, and we're heading into 2018 with even more energy and excitement”. And he adds, “once again we've exceeded our growth estimates, and we continue to consolidate our presence and business figures in mature markets, such as Europe, where there is considerable competition”. Mr. Font also explains that "we’re also continuing to bolster the brand's leading position in very important markets in the industry, such as China, the Middle East, Australia and Latin America”. In fact, the pharmaceutical company is expanding internationally at a constant pace, and in 2017 it succeeded in doubling the business in recently opened countries such as Israel and Costa Rica.

According to the trend of business growth in recent years, mesoestetic Pharma Group plans on maintaining the current pace, increasing the production capacity of its most strategic lines and expanding its staff. The company's growth strategy will be based not only on research and innovation, but also on the launch of products and treatments of reference, such as injectable medical devices, with which it will remain at the cutting edge and be a benchmark. 

Innovation and Industry 4.0, the driving force behind mesoestetic’s evolution

2017, a year marked by digitisation

“mesoestetic's growth wouldn't be possible without the major advances in the digitisation efforts that we’ve been making in recent years”, Font explains. “In 2017 we focused a large part of our efforts on implementing the new ERP in conjunction with Indra-Tecnocom, with whom we’ll optimise the management work of all areas of the company”.

Together with the new management system, mesoestetic presented in 2017 its new corporate web site, where the realities of end consumers and aesthetic professionals share the same space. In addition, the web site offers much more information not only about mesoestetic's treatments but also trends and recommendations in the medical-aesthetic sector.

2018, commitment to Industry 4.0                                                     

Innovation and research are part of mesoestetic's DNA. An example of this is the company's commitment to focusing its strategy on Industry 4.0, technology, artificial intelligence and continuing research to improve and optimise processes and operations.

In this regard and as a result of the great period that mesoestetic is experiencing, the firm signed an agreement with the City Government of Viladecans last December to purchase the building site located next to its current headquarters. This space will house the new corporate building, which will have all the necessary features to both satisfy the R&D&I needs of the laboratory and offer the best and most comprehensive training for its partners and customers.

Leadership in aesthetic medicine

Increasingly, men and women of all ages throughout the world are concerned about their look and the image they project. According to the American Academy of Aesthetic Medicine, “patients not only want to be in good health, they also want to enjoy life to the fullest, be fit and minimize the effects of normal aging”. However, highly invasive surgical procedures are decreasing, while treatments with injectables or chemical peelings (among others) are on the rise, and natural, non-exaggerated finishes are given priority.

Likewise, according to the predictions of the International Association for Physicians in Aesthetic Medicine (IAPAM), the aesthetic medicine market will reach 6.5 billion dollars throughout the world. Some of the treatments that are going to experience the greatest demand include rejuvenation of women's intimate areas and of the eye contours, as well as remodelling of the facial oval, among others.

The majority of mesoestetic's research is being developed along this line. For over 5 years its products for medical use have included mesohyal™, the most extensive range of intra-dermal administration medical devices (class III) for aesthetic treatments, and for 2 years it has had mesofiller®, a family of dermal injectables of reticulated hyaluronic acid. These lines currently constitute the company’s most strategic ones, in which the laboratory is making big investments in R&D and for which the company plans on increasing its production capacity to handle the growing demand for these types of devices.

In brief, 2018 will be a year in which mesoestetic Pharma Group, is clearly committed to staying at the cutting edge of aesthetic medicine by making big investments in research and development and by defining the expansion of the corporate headquarters, including new, state-of-the-art facilities designed to achieve the R&D&I goals of a benchmark company in the sector.